Studies bowel preparation and colonoscopy safety in people with heart, kidney or liver disease
Observes bowel cleansing and colonoscopy in adults with chronic heart, kidney or liver disease.
Key facts
- Who runs it
- Asian Institute of Gastroenterology, India
- Where
- Hyderabad, IndiaSee the site
- Trial code
- Registry title
- Safety, Efficacy and Tolerability of Bowel Preparation and Colonoscopy in Patient With CHD, CKD and CLD
- Status
- Recruiting
- People taking part
- 74 people, planned
- Started
- 10 Aug 2024
- Planned end
- 30 May 2025
- Type of study
- Observational
- Treatments tested
- Colonoscopy
- Record updated
- 13 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with long-term heart, kidney or liver disease who are planned for a colonoscopy. It studies how safe and well tolerated the bowel preparation is.
- Age
- Adults over 18 years, up to 75 years
- Sex
- All sexes can join
- Disease stage
- Diagnosed chronic heart disease, chronic kidney disease or chronic liver failure, planned for a colonoscopy that is not an emergency
Main reasons for not taking part
- Current or past bowel blockage or bowel surgery that removed part of the bowel
- Known allergy to PEG
- Emergency colonoscopy
- Pregnant or breastfeeding women
- Paralytic ileus or bowel perforation
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Adult >18 years
- Diagnosed cases of chronic heart disease, chronic kidney disease or chronic liver failure planned for elective colonoscopy
Who cannot take part
- Current or past history of bowel obstruction or resection
- Known allergies to PEG
- Paralytic ileus / Bowel perforation
- Age < 18 years
- Emergency colonoscopies
- Pregnant or lactating women
- Inability to protect airway
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in India
- Asian Institute of Gastroenterology/AIG HospitalsHyderabad, IndiaContact: Dr Mohan Ramchandani, MBBS MD DMTaking people
About the trial
What the trial wants to find out
Consecutive eligible patients will be enrolled and written informed consent will be obtained from all participants. Routine blood investigations will be sent. Patients with chronic heart failure will be classified based on ejection fraction into 2 groups (EF </> 40%), patients with chronic kidney disease will be classified based on KDIGO classification system into grade I-V. Patients with chronic liver disease will be classified according to the child pugh scoring system into three groups (Child A, B and C). All patients will be undergo bowel preparation under supervision. The patients will be given 10 mg of bisacodyl, the night before colonoscopy. A PEG sachet (137.15 g) containing polyethylene glycol (118 g), sodium chloride (2.93 g), potassium chloride (1.484 g), sodium bicarbonate (3.370 g), and anhydrous sodium sulfate (11.36 g) will be constituted into 2 L solution and used for bowel preparation.
Read full original descriptionShow less
Patients will receive 1 L of PEG solution between 10 PM and 11 PM the day before and 1 L of PEG solution between 6 AM and 7 AM on the day of colonoscopy. Clear liquids will be allowed after the completion of the last bowel preparation until the start of the procedure. Liquid diet includes soups, fruit juices, rice kanji, or porridge in liquid consistency, and clear liquids such as coconut water and lemon juice.
After the adequacy of bowel preparation is deemed fit, the patients will be taken for colonoscopic examination. A single blinded outcome assessment will be done by the colonoscopist/endoscopist performing the procedure (adequacy of bowel preparation) and the endoscopy nurse (tolerability and compliance).
Colonoscopy will be performed using standard video colonoscopes (Olympus, Tokyo, Japan) between 11:00 AM and 1:00 PM without sedation. The colonoscopist / endoscopist will assess the adequacy of bowel preparation using the Boston Bowel Preparation Scale (BBPS). Excellent, good and poor bowel preparations will be defined by BBPS score of 9, 6 - 9 and < 6, respectively. (12-14) Blood sampling will be done before bowel preparation and after colonoscopy in all patients for measurement of baseline parameters, renal function status (Serum creatinine, serum urea), serum electrolytess (serum sodium, serum potassium, serum phosphate and serum calcium) and haematocrit.
Assessment of safety and tolerability will be performed using clinical examination and symptom questionnaire. Cardiovascular and gastrointestinal (GI) symptoms will be recorded. Cardiovascular symptoms such as dyspnea, palpitations, chest pain, will be recorded and scored using the NYHA classification system for symptom severity. Clinical examination will be carried out post-bowel preparation and post-procedure to assess for signs of fluid overload, i.e. auscultation for crepitations and measurement of JVP. GI symptoms such as nausea, abdominal pain, vomiting, dizziness, bloating, and headache will be recorded and scored on a 4-point scale: 1 = none, 2 = mild, 3 = moderate, and 4 = severe. The compliance of bowel preparation will be defined as "poor" for patients who consume less than 75% of the PEG preparation.
Treatments tested
- Colonoscopy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Safety, Efficacy and Tolerability of Bowel Preparation and Colonoscopy in Patient With Chronic Heart Disease, Chronic Kidney Disease and Chronic Liver Disease
- Plain-language title
- Studies bowel preparation and colonoscopy safety in people with heart, kidney or liver diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06874036, who can take part
- Record updated
- 13 March 2025